---
schema_version: "secwatch.filing_event.v1"
accession: "0001087294-26-000053"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2026-06-25T21:00:32+00:00"
generated_at: "2026-06-25T21:02:54.361080+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve sale of Cumberland's FDA-approved products to Apotex

## Summary
- Shareholders voted 10,492,455 For (99.84% of votes cast), 15,904 Against, 1,267 Abstain.
- Transaction involves sale of FDA-approved commercial products and related assets to Apotex Inc.
- Approval allows Cumberland to integrate products with Apotex's U.S. branded business per April 22, 2026 APA.
- Special meeting held June 24, 2026; quorum of 70.14% of outstanding shares (10,509,626 shares represented).

## SEC filing metadata
- accession: 0001087294-26-000053
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2026-06-25T21:00:32+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000053/0001087294-26-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000053/cpix-20260624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001087294-26-000053
- JSON: https://secwatch.observer/filing/0001087294-26-000053.json
- Plain text: https://secwatch.observer/filing/0001087294-26-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.